Archived This bill is from the 117th Congress (2021–2022) and is no longer under active consideration.
Expressing the sense of the House of Representatives that decades of policies rooted in socialism have stifled United States domestic pharmaceutical drug manufacturing and left the United States exposed to the hostile actions and unfair trade practices of the People's Republic of China.
House: Referred